Revelation Biosciences Achieves GMP Milestone for Chronic Kidney Disease Treatment with Gemini

Revelation Biosciences Achieves Key Manufacturing Milestone for Chronic Kidney Disease Treatment

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies, announces a significant advancement in the development of its lead product, Gemini. The company successfully completes Good Manufacturing Practice (GMP) compliant manufacturing of this drug product, a crucial prerequisite for submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This milestone positions Revelation to move forward with its planned Phase 1b clinical trial targeting patients with chronic kidney disease (CKD) and lays the groundwork for subsequent Phase 2 studies. The successful GMP manufacturing underscores the company's commitment to advancing therapeutic options for conditions that currently lack effective treatments.

CEO James Rolke expresses enthusiasm regarding this accomplishment, emphasizing the importance of the upcoming clinical trials. He anticipates that the top-line results, which encompass critical data on pharmacokinetics, pharmacodynamics, and safety, will be available in the first half of 2025. The Gemini formulation, which utilizes phosphorylated hexaacyl disaccharide (PHAD®), is designed to address inflammation by reprogramming the innate immune system. The strategy aims to enhance the body's response to various stressors, including trauma and infection. This innovative approach reflects Revelation's dedication to leveraging trained immunity for the development of effective therapies.

Preclinical studies have shown promising results regarding Gemini's therapeutic potential, as it has already met primary safety endpoints in previous Phase 1 trials. These trials demonstrated significant pharmacodynamic activity, reflected in favorable changes in biomarkers such as IL-10. Revelation's ongoing initiatives include utilizing Gemini not only to slow CKD progression but also to prevent acute kidney injury and reduce post-surgical infection severity. The company’s multi-faceted approach to addressing these critical health issues showcases its commitment to finding solutions that can improve patient outcomes and enhance overall healthcare.

In addition to the advancement of the Gemini product, Revelation Biosciences remains focused on expanding its research into new therapeutic applications. The company's work in reprogramming the innate immune system represents a forward-thinking strategy in the biopharmaceutical sector, addressing unmet medical needs through innovative science. As the company prepares for its clinical trials, it is poised to contribute significantly to the field of immunotherapy and chronic disease management.

The successful completion of GMP manufacturing not only marks a pivotal moment for Revelation Biosciences but also highlights the potential impact of its research on the treatment landscape for chronic kidney disease. With a strong pipeline and a commitment to innovative therapies, the company is well-positioned to make significant strides in addressing serious health challenges. For more information on their developments, visit www.RevBiosciences.com.